With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid,as a common compound, the synthetic route is as follows.
Intermediate 8: 1 ,1-dimethylethyl 6-{r(5-methyl-1-{r2-(methyloxy)phenyllmethyl}-1 H-pyrazol- 3-yl)amino1carbonyl}-3,4-dihvdro-2(1 H)-isoquinolinecarboxylate; To a solution of 5-methyl-1-{[2-(methyloxy)phenyl]methyl}-1 /-/-pyrazol-3-amine (Intermediate 5) (0.1 g, 0.46 mmol) in DCM (5m L) was added 2-{[(1 ,1-dimethylethyl)oxy]carbonyl}-1 ,2,3,4- tetrahydro-6-isoquinolinecarboxylic acid (0.15 g, 0.55 mmol), HOBt (0.075 g, 0.55 mmol) and EDCI (0.105 g, 0.55 mmol), Et3N (130 muL, 0.92 mmol) and the mixture was stirred at room temperature for 48 hours. The organic phase was then washed with HCI (0.5N) and a saturated solution of NaHCO3, dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography eluting with DCM to DCM/EtOAc: 80/20 to give the title compound as an oil (115 mg, 52%). LC/MS: m/z 477 (M+H)+, Rt: 3.52 min.
170097-67-3, The synthetic route of 170097-67-3 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2008/74833; (2008); A2;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem